- call +1-201-465-4211
- email sales@mrinsights.biz
Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.
Scope of the Report:
This report studies the Solid Tumors Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Solid Tumors Drugs market by product type and applications/end industries.
During 2017, the biologics segment dominated the market and accounted for close to 55% of the market share in terms of revenue. This segment consists of medicinal products extracted from biological sources such as human, animal, microorganisms, or they are manufactured using the latest, cutting-edge biotechnological processes. Biologics include products such as enzymes, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.
In terms of geography, the Americas dominated the global solid tumors drugs market. The growth of this market in the Americas is attributed to the increasing uptake of existing biologics drugs and the launch of new biologics. However, the revenue from these drugs will decrease during the forecast period because of the loss of patent exclusivity of drugs, leading to the entry of generics. This decline is expected to be partially offset by favorable reimbursement plans by the government, such as the provision of Medicare and Medicaid. The US is the largest revenue contributor in this region.
The global Solid Tumors Drugs market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Solid Tumors Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
Eli Lilly
GSK
Merck
Sanofi
AbbVie
AstraZeneca
Bayer
Biogen
Boehringer Ingelheim
Boston Biomedical
Daiichi Sankyo
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Small Molecules
Biologics
Market Segment by Applications, can be divided into
Hospitals
Clinics
Academic and Research Institutes
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Solid Tumors Drugs Market Overview
1.1 Product Overview and Scope of Solid Tumors Drugs
1.2 Classification of Solid Tumors Drugs by Types
1.2.1 Global Solid Tumors Drugs Revenue Comparison by Types (2017-2023)
1.2.2 Global Solid Tumors Drugs Revenue Market Share by Types in 2017
1.2.3 Small Molecules
1.2.4 Biologics
1.3 Global Solid Tumors Drugs Market by Application
1.3.1 Global Solid Tumors Drugs Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Academic and Research Institutes
1.4 Global Solid Tumors Drugs Market by Regions
1.4.1 Global Solid Tumors Drugs Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Solid Tumors Drugs Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Solid Tumors Drugs Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Solid Tumors Drugs Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Solid Tumors Drugs Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Solid Tumors Drugs Status and Prospect (2013-2023)
1.5 Global Market Size of Solid Tumors Drugs (2013-2023)
2 Manufacturers Profiles
2.1 Hoffmann-La Roche
2.1.1 Business Overview
2.1.2 Solid Tumors Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Hoffmann-La Roche Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis
2.2.1 Business Overview
2.2.2 Solid Tumors Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.3 Celgene
2.3.1 Business Overview
2.3.2 Solid Tumors Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Celgene Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.4 Johnson & Johnson
2.4.1 Business Overview
2.4.2 Solid Tumors Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Johnson & Johnson Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.5 Pfizer
2.5.1 Business Overview
2.5.2 Solid Tumors Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.6 BMS
2.6.1 Business Overview
2.6.2 Solid Tumors Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 BMS Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.7 Eli Lilly
2.7.1 Business Overview
2.7.2 Solid Tumors Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Eli Lilly Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.8 GSK
2.8.1 Business Overview
2.8.2 Solid Tumors Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 GSK Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.9 Merck
2.9.1 Business Overview
2.9.2 Solid Tumors Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Merck Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.10 Sanofi
2.10.1 Business Overview
2.10.2 Solid Tumors Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Sanofi Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.11 AbbVie
2.11.1 Business Overview
2.11.2 Solid Tumors Drugs Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 AbbVie Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.12 AstraZeneca
2.12.1 Business Overview
2.12.2 Solid Tumors Drugs Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 AstraZeneca Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.13 Bayer
2.13.1 Business Overview
2.13.2 Solid Tumors Drugs Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Bayer Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.14 Biogen
2.14.1 Business Overview
2.14.2 Solid Tumors Drugs Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Biogen Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.15 Boehringer Ingelheim
2.15.1 Business Overview
2.15.2 Solid Tumors Drugs Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Boehringer Ingelheim Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.16 Boston Biomedical
2.16.1 Business Overview
2.16.2 Solid Tumors Drugs Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Boston Biomedical Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.17 Daiichi Sankyo
2.17.1 Business Overview
2.17.2 Solid Tumors Drugs Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Daiichi Sankyo Solid Tumors Drugs Revenue, Gross Margin and Market Share (2016-2017)
3 Global Solid Tumors Drugs Market Competition, by Players
3.1 Global Solid Tumors Drugs Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Solid Tumors Drugs Players Market Share
3.2.2 Top 10 Solid Tumors Drugs Players Market Share
3.3 Market Competition Trend
4 Global Solid Tumors Drugs Market Size by Regions
4.1 Global Solid Tumors Drugs Revenue and Market Share by Regions
4.2 North America Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
4.3 Europe Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
4.5 South America Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
5 North America Solid Tumors Drugs Revenue by Countries
5.1 North America Solid Tumors Drugs Revenue by Countries (2013-2018)
5.2 USA Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
5.3 Canada Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
5.4 Mexico Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
6 Europe Solid Tumors Drugs Revenue by Countries
6.1 Europe Solid Tumors Drugs Revenue by Countries (2013-2018)
6.2 Germany Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
6.3 UK Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
6.4 France Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
6.5 Russia Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
6.6 Italy Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Solid Tumors Drugs Revenue by Countries
7.1 Asia-Pacific Solid Tumors Drugs Revenue by Countries (2013-2018)
7.2 China Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
7.3 Japan Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
7.4 Korea Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
7.5 India Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
8 South America Solid Tumors Drugs Revenue by Countries
8.1 South America Solid Tumors Drugs Revenue by Countries (2013-2018)
8.2 Brazil Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
8.3 Argentina Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
8.4 Colombia Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Solid Tumors Drugs by Countries
9.1 Middle East and Africa Solid Tumors Drugs Revenue by Countries (2013-2018)
9.2 Saudi Arabia Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
9.3 UAE Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
9.4 Egypt Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
9.5 Nigeria Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
9.6 South Africa Solid Tumors Drugs Revenue and Growth Rate (2013-2018)
10 Global Solid Tumors Drugs Market Segment by Type
10.1 Global Solid Tumors Drugs Revenue and Market Share by Type (2013-2018)
10.2 Global Solid Tumors Drugs Market Forecast by Type (2018-2023)
10.3 Small Molecules Revenue Growth Rate (2013-2023)
10.4 Biologics Revenue Growth Rate (2013-2023)
11 Global Solid Tumors Drugs Market Segment by Application
11.1 Global Solid Tumors Drugs Revenue Market Share by Application (2013-2018)
11.2 Solid Tumors Drugs Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Academic and Research Institutes Revenue Growth (2013-2018)
12 Global Solid Tumors Drugs Market Size Forecast (2018-2023)
12.1 Global Solid Tumors Drugs Market Size Forecast (2018-2023)
12.2 Global Solid Tumors Drugs Market Forecast by Regions (2018-2023)
12.3 North America Solid Tumors Drugs Revenue Market Forecast (2018-2023)
12.4 Europe Solid Tumors Drugs Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Solid Tumors Drugs Revenue Market Forecast (2018-2023)
12.6 South America Solid Tumors Drugs Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Solid Tumors Drugs Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Solid Tumors Drugs Picture
Table Product Specifications of Solid Tumors Drugs
Table Global Solid Tumors Drugs and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
